Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
6-1 Month Momentum % is the total return of the stock from 6-month ago to 1-month ago. As of today (2026-08-21), Kwality Pharmaceuticals's 6-1 Month Momentum % is N/A%.
The industry rank for Kwality Pharmaceuticals's 6-1 Month Momentum % or its related term are showing as below:
NSE:KPL's 6-1 Month Momentum % is not ranked *
in the Drug Manufacturers industry.
Industry Median: -11.27 * Ranked among companies with meaningful 6-1 Month Momentum % only.
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 6-1 Month Momentum % measures the total return to a stock over the past six months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
Kwality Pharmaceuticals 6-1 Month Momentum % Related Terms
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kwality Pharmaceuticals (NSE:KPL) has a 6-1 Month Momentum % of N/A% as of Aug. 21, 2026. 6-1 Month Momentum measures the total return of the stock from 6-month ago to 1-month ago. View historical data on Kwality Pharmaceuticals and its competitors. According to the industry distribution chart, Kwality Pharmaceuticals ranks #29 out of 1026 companies in the Drug Manufacturers industry, placing it in the top 2.8%.
Is Kwality Pharmaceuticals' 6-1 Month Momentum % too high?
Kwality Pharmaceuticals' current 6-1 Month Momentum % is N/A%. Based on the distribution chart, Kwality Pharmaceuticals ranks #29 out of 1026 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Kwality Pharmaceuticals has a GF Score™ of 60/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Kwality Pharmaceuticals' 6-1 Month Momentum % compare to ?
According to the Drug Manufacturers industry distribution chart, Kwality Pharmaceuticals ranks #29 out of 1026 companies for 6-1 Month Momentum %. This places Kwality Pharmaceuticals in the top 3% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 6-1 Month Momentum % for a Drug Manufacturers company?
A good 6-1 Month Momentum % depends on the Drug Manufacturers industry context. However, 6-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 6-1 Month Momentum % mean?
A high 6-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 6-1 Month Momentum measures the total return of the stock from 6-month ago to 1-month ago. View historical data on Kwality Pharmaceuticals and its competitors. Kwality Pharmaceuticals's current 6-1 Month Momentum % is N/A%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kwality Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Kwality Pharmaceuticals (NSE:KPL) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹1,332.01, compared to a current price of ₹3,630.30 — trading 172.5% above its estimated fair value. The current 6-1 Month Momentum % is N/A%. Kwality Pharmaceuticals' overall GF Score™ is 60/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 6-1 Month Momentum % calculated?
6-1 Month Momentum % is calculated from a company's financial statements. For Kwality Pharmaceuticals (NSE:KPL), the current 6-1 Month Momentum % is N/A% as of Aug. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Kwality Pharmaceuticals (NSE:KPL) Overvalued in 2026?
Based on GuruFocus' analysis, Kwality Pharmaceuticals stock appears to be overvalued.
The current stock price of ₹3,630.30 is trading 172.5% above its estimated GF Value™ of ₹1,332.01.
GuruFocus considers Kwality Pharmaceuticals to be Significantly Overvalued.
Key valuation signals for NSE:KPL:
6-1 Month Momentum %: N/A%
GF Value™: ₹1,332.01 vs. price of ₹3,630.30 (172.5% above fair value)
No single metric tells the full story. See the NSE:KPL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Kwality Pharmaceuticals Ltd is an India-based pharmaceutical company. It is principally engaged in manufacturing finished pharmaceutical formulations in a dosage form. The company manufactures and exports pharmaceutical formulations in liquid orals, dry syrups, tablets, capsules, sterile powder for injections, and small-volume injectables.
60GF Score
Get the complete analysis for NSE:KPL
6-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:KPL has been successfully added to your 
